Benzodiazepines: Classification, Drugs, Doses, and Mechanism of Action
Mechanism of Action
Benzodiazepines enhance the activity of the inhibitory neurotransmitter GABA by binding to the GABAA receptor, producing anxiolytic, sedative, amnestic, anticonvulsant, and muscle relaxant effects without analgesic activity 1, 2. They act as positive allosteric modulators of the ionotropic GABAA receptor, enhancing inhibitory synaptic transmission 3.
Classification System
Benzodiazepines can be conceptualized using a 2x2 classification based on:
- Receptor affinity for the benzodiazepine-binding site of the GABA-A receptor 4
- Pharmacokinetics (half-life and metabolism) 4
By Duration of Action (Most Clinically Relevant)
Short-Acting Benzodiazepines
Triazolam 5
- Dosage forms: 0.125 mg, 0.25 mg tablets
- Standard adult dose: 0.25 mg at bedtime; maximum 0.5 mg
- Elderly/debilitated dose: 0.125 mg at bedtime; maximum 0.25 mg
- Primary use: Sleep-onset insomnia
- Onset: 1-2 minutes IV; peak effect 3-4 minutes
- Duration: 15-80 minutes
- Elimination half-life: 3-11 hours
- Standard adult dose (IV): 1-2 mg (max 0.03 mg/kg) over 1-2 minutes
- Additional doses: 1 mg at 2-minute intervals until adequate sedation
- Elderly (>60 years) or ASA ≥3: Reduce dose by 20% or more
- Maximum total dose: Usually ≤6 mg
- Loading dose: 0.01-0.05 mg/kg over several minutes
- Maintenance infusion: 0.02-0.1 mg/kg/hr
Short- to Intermediate-Acting Benzodiazepines
Estazolam 5
- Dosage forms: 1 mg, 2 mg tablets
- Standard adult dose: 1-2 mg at bedtime
- Elderly/debilitated dose: 0.5 mg at bedtime
- Dosage forms: 7.5 mg, 15 mg, 30 mg capsules
- Standard adult dose: 15-30 mg at bedtime
- Elderly/debilitated dose: 7.5 mg at bedtime
- Onset: 15-20 minutes IV
- Elimination half-life: 8-15 hours
- No active metabolites
- Loading dose (IV): 0.02-0.04 mg/kg (≤2 mg)
- Maintenance: 0.02-0.06 mg/kg every 2-6 hours PRN or 0.01-0.1 mg/kg/hr (≤10 mg/hr)
- More potent than midazolam and diazepam
Oxazepam 6
- Specific dosing varies by indication
Long-Acting Benzodiazepines
Flurazepam 5
- Dosage forms: 15 mg, 30 mg capsules
- Standard adult dose: 15-30 mg at bedtime
- Elderly/debilitated dose: 15 mg at bedtime
- Caution: Risk of residual daytime drowsiness; rarely prescribed due to extended half-life
- Onset: 2-5 minutes IV
- Elimination half-life: 20-120 hours
- Has active metabolites that prolong sedation, especially in renal failure
- Standard adult dose (IV): 5-10 mg over 1 minute for endoscopic sedation
- Additional doses: At 5-minute intervals
- Total dose: Usually 10 mg sufficient; up to 20 mg if no narcotic co-administered
- Elderly/debilitated: Dose reduction required
Common Clinical Uses by Drug
For Insomnia 5
- Sleep-onset insomnia: Triazolam, estazolam, temazepam
- Sleep maintenance insomnia: Estazolam, temazepam (longer-acting options)
- Avoid flurazepam due to residual daytime sedation risk
For Procedural Sedation 1
- Midazolam preferred over diazepam for endoscopic procedures due to:
- More rapid onset and shorter duration
- Better patient tolerance
- Superior amnestic properties
- Less thrombophlebitis
- Fewer adverse events including respiratory depression
- Diazepam used less frequently but remains an option
For Anxiety/Agitation 6
- Lorazepam, oxazepam, temazepam for anxiety management
- Caution: Regular use leads to tolerance, addiction, depression, and cognitive impairment
- Paradoxical agitation occurs in ~10% of patients
- Infrequent, low doses of short half-life agents are least problematic
Critical Safety Considerations
Dose-Dependent Respiratory Depression 1
- Major adverse effect across all benzodiazepines
- Synergistic effect when combined with opioids—requires dose reduction of benzodiazepine
- Higher risk in patients with underlying respiratory disease (asthma, COPD, sleep apnea)
- Depression of central ventilatory response to hypoxia and hypercapnea
Special Populations Requiring Dose Reduction 5, 2
- Elderly patients: 20-50% dose reduction required
- Debilitated patients: Reduced dosing mandatory
- Hepatic impairment: Dose adjustment needed (especially midazolam)
- Renal impairment: Midazolam clearance reduced; lorazepam preferred over diazepam in renal failure
- Obese patients: Midazolam clearance reduced
Withdrawal and Dependence 5, 7, 3
- Rapid dose decrease or abrupt discontinuation produces withdrawal symptoms including rebound insomnia, similar to barbiturates and alcohol
- Prolonged use risks tolerance and physical dependence
- Tolerance mediated by GABAA receptor downregulation and compensatory glutamatergic system sensitization
- Management: Comprehensive psychological intervention with pharmacological substitution (switch to long-acting benzodiazepine) and gradual dose tapering
Contraindications and Warnings 5, 8
- Not recommended during pregnancy or nursing
- Caution with depression, compromised respiratory function, hepatic/heart failure
- Safety/effectiveness in patients <18 years not established
- Additive psychomotor impairment with CNS depressants and alcohol
- Do not prescribe benzodiazepines for functional seizures without co-occurring epilepsy or another specific indication
- Associated with complex behaviors: sleepwalking, sleep-eating, sleep-driving, sexual behavior
- Observational data links hypnotics to dementia (HR 2.34)
Drug Interactions 1, 2
- Propylene glycol toxicity with lorazepam: Risk of acidosis and nephrotoxicity
- Midazolam clearance reduced in elderly, obese, hepatic/renal impairment
- Active metabolites of diazepam prolong sedation in renal failure
Reversal Agent
Flumazenil (benzodiazepine antagonist) 1
- Caution: May induce seizures or withdrawal reactions in benzodiazepine-tolerant patients
- Should not be used routinely for reversal in chronic benzodiazepine users
Administration Pearls 5
- Administer on empty stomach to maximize effectiveness
- Allow appropriate sleep time (minimum 4-5 hours in bed)
- Avoid combination with alcohol, other sedatives, or sleep restriction
- Monitor for daytime memory and psychomotor impairment